Ertapenem Neurotoxicity in Hemodialysis Patients-Safe and Effective Dosing Is Still Needed: A Retrospective Study and Literature Review.

Wasim S El Nekidy Hazem ElrefaeiTerrence J Lee St JohnNizar M AttallahFarah KablaouiAhmad NusairBartlomiej Piechowski-JozwiakJanise PhillipsIslam M Ghazi

Published in: The Annals of pharmacotherapy (2020)

The currently approved ertapenem dose imposes a risk of developing neurotoxicity in patients with CKD-5D. Utilizing the published data in this population, alternative post-dialysis dosing strategies administered through dialysis access such as 1 g loading dose, followed by either 0.5 g (for the 48 hours interdialytic time) or 1 g (for the 72 hours interdialytic time) might warrant further investigation for efficacy and safety.

Keyphrases

chronic kidney disease
end stage renal disease
peritoneal dialysis
case report
electronic health record
big data
randomized controlled trial
machine learning
data analysis
artificial intelligence